8-K: Immunocore Converts Phase 2/3 Melanoma Trial to Pivotal Phase 3 Study Following FDA Consultation

Immunocore's TEBE-AM Phase 2/3 clinical trial for advanced cutaneous melanoma has been converted to a single Phase 3 registrational trial after discussions with the FDA, aiming to accelerate the approval process for KIMMTRAK.

Summary

• Immunocore has announced that its TEBE-AM Phase 2/3 clinical trial for previously treated advanced cutaneous melanoma will now proceed as a single Phase 3 registrational trial.
• This decision follows a consultation with the U.S. Food and Drug Administration (FDA).
• The trial will evaluate KIMMTRAK, both as a monotherapy and in combination with pembrolizumab, against a control arm.
• All patients randomized from the start of the TEBE-AM Phase 2/3 trial will be included in the Phase 3 intent-to-treat population.
• The primary endpoint of the Phase 3 trial is overall survival.
• The conversion to a Phase 3 trial is expected to accelerate the time to final overall survival analysis.
• The company anticipates that the Phase 3 trial will be mostly enrolled by the time the Phase 2 overall survival data would have matured.
• The three-arm Phase 3 design will allow for more robust testing of KIMMTRAK.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic decision to accelerate the clinical trial process for KIMMTRAK, which has already shown promise in other indications. The conversion to a Phase 3 trial and the inclusion of all patients from the start of the trial are positive developments. However, the document also acknowledges the risks associated with the drug and the clinical trial process, preventing a perfect score.

Positives

• The conversion to a Phase 3 trial is expected to accelerate the time to final overall survival analysis.
• The three-arm Phase 3 design will allow for more robust testing of KIMMTRAK.
• Including all patients randomized to date in the intent-to-treat population will accelerate the time to final analysis.
• KIMMTRAK has shown promising clinical activity in Phase 1 cutaneous melanoma trials.
• KIMMTRAK has already been approved for uveal melanoma, demonstrating its potential.

Negatives

• The document highlights the risk of Cytokine Release Syndrome (CRS) with KIMMTRAK, which can be serious or life-threatening.
• Skin reactions and elevated liver enzymes are also common adverse reactions associated with KIMMTRAK.
• The document mentions the potential for embryo-fetal toxicity, requiring contraception during treatment.

Risks

• The company's ability to conduct ongoing and planned clinical trials is subject to risks and uncertainties.
• Obtaining and maintaining regulatory approval for KIMMTRAK, including expanded indications, is not guaranteed.
• Delays in clinical trials, whether due to patient enrollment or other factors, could impact timelines.
• The company faces competition in the market for cancer therapies.
• Unexpected safety or efficacy data from trials could affect the approval process.
• Actions by regulatory agencies could impact the initiation, timing, and progress of clinical trials.
• The company's ability to obtain additional funding is subject to market conditions and other factors.

Future Outlook

The company anticipates that the Phase 3 trial will be mostly enrolled by the time the Phase 2 overall survival data would have matured, and expects to accelerate the time to final analysis of the Phase 3 trial.

Management Comments

• Mark Moyer, SVP, Regulatory Affairs, stated that the decision to launch a registrational trial in cutaneous melanoma was based on KIMMTRAK's overall survival benefit in uveal melanoma and promising clinical activity in Phase 1 cutaneous melanoma trials.
• He also mentioned that the decision to amend the protocol into a single Phase 3 registrational study was made in consultation with the FDA to allow robust testing of two KIMMTRAK regimens and to accelerate the time to primary analysis.

Industry Context

This announcement is significant as it reflects a strategic shift in Immunocore's clinical development program for KIMMTRAK, focusing on a more efficient path to potential approval for cutaneous melanoma. The move aligns with the industry's trend towards accelerated development pathways and the use of combination therapies to improve patient outcomes in cancer treatment.

Comparison to Industry Standards

• The conversion of a Phase 2/3 trial to a Phase 3 trial is a common strategy to expedite the regulatory approval process, similar to other companies developing oncology drugs.
• The use of overall survival as the primary endpoint is standard for registrational trials in oncology, aligning with industry benchmarks.
• The inclusion of a combination therapy arm (KIMMTRAK with pembrolizumab) reflects the growing trend of combining immunotherapies to enhance efficacy, similar to strategies employed by companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
• The 75% one-year overall survival rate in the Phase 1b trial is promising and compares favorably to historical outcomes in advanced melanoma, although direct comparisons are difficult without full trial data.

Stakeholder Impact

• Shareholders may view this as a positive development, potentially leading to faster approval and commercialization of KIMMTRAK for cutaneous melanoma.
• Patients with advanced cutaneous melanoma may benefit from a new treatment option.
• Employees of Immunocore will be involved in the execution of the Phase 3 trial and the regulatory approval process.
• The company's suppliers and partners may see increased activity related to the trial.

Next Steps

• The company will continue to enroll patients in the Phase 3 trial.
• The company will monitor patients for safety and efficacy.
• The company will analyze the data from the Phase 3 trial.
• The company will seek regulatory approval for KIMMTRAK in cutaneous melanoma.

Key Dates

Keywords

KIMMTRAK, cutaneous melanoma, clinical trial, Phase 3, FDA, immunotherapy, Tebentafusp, melanoma, overall survival, ImmTAC, cancer